Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes.

This study is not recruiting patients in the United States.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: 2-Aminopurine; Famciclovir

Criteria

Inclusion Criteria:

• Diagnosis of genital herpes

• Had at least 2 recurrences in past 12 months or 1 recurrence in past 6 months

Exclusion Criteria:

• - Currently taking suppressive herpes antiviral therapy

• Females who are pregnant, breast feeding or planning to become pregnant during study

• History of allergy to famciclovir or similar products (e.g. aciclovir, valaciclovir)

Other protocol-defined exclusion criteria may apply.